Fate Therapeutics Inc (NASDAQ:FATE) has been given an average rating of “Buy” by the seventeen ratings firms that are presently covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month […]
